Liu Zhaoming, Li Zhen, Xu Binghui, Yao Hao, Qi Shuangyu, Tai Jianxiong
Department of Hepatobiliary Surgery, Harrison International Peace Hospital, Hengshui, Hebei 053000, People's Republic of China.
Department of Interventional Therapy, Harrison International Peace Hospital, Hengshui, Hebei 053000, People's Republic of China.
Cancer Manag Res. 2020 Oct 29;12:10749-10762. doi: 10.2147/CMAR.S263619. eCollection 2020.
Long noncoding RNAs are differentially expressed in hepatocellular carcinoma (HCC) and have been validated as essential regulators in HCC. However, there is limited knowledge regarding the detailed roles and mechanisms of most lncRNAs in HCC cells. In this study, the expression profiles of PRR34 antisense RNA 1 () in HCC tissues and cell lines were determined. In addition, the detailed roles and underlying mechanisms of PRR34-AS1 in HCC cells were comprehensively elucidated.
Reverse transcription-quantitative polymerase chain reaction (PCR) was performed to measure expression in HCC cells. Cell proliferation, apoptosis, and migration and invasion were evaluated in vitro using the cell counting kit-8 (CCK-8) assay, flow cytometric analysis, and transwell cell migration and invasion assays, respectively. In vivo tumor growth was determined using tumor xenograft experiments. The potential miRNA targets of were predicted via bioinformatic analysis and further confirmed using the luciferase reporter assay, RNA immunoprecipitation assay, and reverse transcription-quantitative PCR.
was highly expressed in HCC tissues and cell lines, and its interference suppressed HCC cell proliferation, migration, and invasion but promoted cell apoptosis in vitro. In addition, loss of decreased tumor growth in HCC cells in vivo. Mechanistically, PRR34-AS1 functions as a sponge and subsequently increases forkhead box O3 () expression in HCC cells. Rescue experiments revealed that the suppressive effects triggered by knockdown on the malignant characteristics of HCC cells could be abrogated by inhibiting or restoring expression.
The depletion of suppresses the oncogenicity of HCC cells by targeting the miR-498/FOXO3 axis. Therefore, the PRR34-AS1/miR-498/FOXO3 pathway may offer a basis for HCC treatment.
长链非编码RNA在肝细胞癌(HCC)中存在差异表达,并且已被证实是HCC中的关键调节因子。然而,关于大多数长链非编码RNA在HCC细胞中的具体作用和机制,我们了解有限。在本研究中,我们测定了PRR34反义RNA 1(PRR34-AS1)在HCC组织和细胞系中的表达谱。此外,我们全面阐明了PRR34-AS1在HCC细胞中的具体作用及潜在机制。
采用逆转录定量聚合酶链反应(PCR)检测PRR34-AS1在HCC细胞中的表达。分别使用细胞计数试剂盒-8(CCK-8)检测法、流式细胞术分析以及Transwell细胞迁移和侵袭实验,在体外评估细胞增殖、凋亡以及迁移和侵袭能力。通过肿瘤异种移植实验测定体内肿瘤生长情况。通过生物信息学分析预测PRR34-AS1潜在的微小RNA(miRNA)靶点,并进一步使用荧光素酶报告基因检测、RNA免疫沉淀检测以及逆转录定量PCR进行验证。
PRR34-AS1在HCC组织和细胞系中高表达,对其进行干扰可抑制HCC细胞的增殖、迁移和侵袭,但在体外促进细胞凋亡。此外,PRR34-AS1缺失可降低HCC细胞在体内的肿瘤生长。机制上,PRR34-AS1作为一种miR-498海绵,随后增加HCC细胞中叉头框O3(FOXO3)的表达。拯救实验表明,抑制miR-498或恢复FOXO3表达可消除PRR34-AS1敲低引发的对HCC细胞恶性特征的抑制作用。
PRR34-AS1的缺失通过靶向miR-498/FOXO3轴抑制HCC细胞的致癌性。因此,PRR34-AS1/miR-498/FOXO3通路可能为HCC治疗提供依据。